Imperative Care Secures $150M Series E Round, Names Healthcare Executive as Vice Chair

Imperative Care, a medical technology innovator focused on treating stroke and ischemic vascular diseases, has successfully closed its Series E funding round with Ally Bridge Group leading the investment. The financing, which reached initial closing with room for additional tranches totaling up to $150 million, underscores strong institutional confidence in the company’s trajectory as it scales operations to serve more patients globally.

The funding syndicate reflects both continued backing and new capital entering the space. Long-standing investors including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, and Pura Vida Investments doubled down on their commitment. Fresh capital came from Catalio Capital Management, HealthCor Family Office, Montreux Growth Partners, and INTAI Technology Corp, signaling broadening market confidence in connected innovations for vascular disease management.

Strategic Leadership Expansion

Alongside the funding announcement, Imperative Care elevated Shacey Petrovic to Vice Chair of its Board of Directors—a newly established position that signals organizational maturation as the company prepares for next-phase growth. Petrovic, who joined the board in 2023, brings substantial operational pedigree. Her previous role as President and CEO of Insulet Corporation, a publicly traded diabetes technology platform, saw the company scale to serve hundreds of thousands of patients worldwide. She currently maintains board positions at Exact Sciences, Ambu A/S, and Axena Health.

In her new capacity, Petrovic will spearhead scaling strategies aimed at expanding patient access to the company’s thrombectomy and peripheral vascular disease treatment solutions. Her appointment reflects a deliberate governance shift toward healthcare executive leadership with proven commercial and clinical track records.

Financing Fuels Clinical Expansion

Fred Khosravi, Chairman and CEO of Imperative Care, positioned the capital raise as pivotal to the company’s hypergrowth agenda. The financing will accelerate investment in proprietary technologies and rigorous clinical evidence generation to document patient outcome improvements. To date, the company’s solutions have been deployed to treat more than 45,000 patients using life-saving vascular intervention technologies.

Ally Bridge founder Frank Yu, who has served as a director since the company’s Series C round in December 2019, highlighted the dramatic progress Imperative Care has demonstrated across multiple fronts. The investment thesis centers on the company’s dual opportunity: strengthening its established position in acute ischemic stroke treatment while preparing infrastructure for broader peripheral vascular disease applications—a market with substantial unmet clinical need.

Market Context

Imperative Care represents the growing convergence of medical device innovation and digital health infrastructure in vascular disease management. The company’s focus on connected solutions reflects industry-wide movement toward integrated care pathways that reduce time-to-treatment and improve patient outcomes in acute vascular emergencies.

Based in Campbell, California, Imperative Care continues developing technologies designed to address treatment gaps across the patient journey for conditions including stroke, pulmonary embolism, and other ischemic vascular diseases. The Series E capital, along with experienced board governance through Petrovic’s appointment, positions the firm to advance both clinical innovation and commercial scalability in the coming years.